Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective study.
Monteil J, Le Brun-Ly V, Cachin F, Zasadny X, Seitz JF, Mundler O, Selvy M, Smith D, Rullier E, Lavau-Denes S, Lades G, Labrunie A, Lecaille C, Valli N, Leobon S, Terrebonne E, Deluche E, Tubiana-Mathieu N. Monteil J, et al. Among authors: mundler o. Dig Liver Dis. 2021 Feb;53(2):231-237. doi: 10.1016/j.dld.2020.10.012. Epub 2020 Nov 2. Dig Liver Dis. 2021. PMID: 33153929 Free article. Clinical Trial.
[Role of FDG-PET scanning in stage IIIAN2 non-small cell lung cancer].
Colavolpe C, Bonardel G, Guedj E, Cammilleri S, Mundler O, Barlesi F. Colavolpe C, et al. Among authors: mundler o. Rev Mal Respir. 2012 Feb;29(2):149-60. doi: 10.1016/j.rmr.2011.05.017. Epub 2012 Jan 9. Rev Mal Respir. 2012. PMID: 22405110 Review. French.
18FDG-PET/CT imaging of external ear sarcoidosis.
Guedj E, Chiche L, Basely M, Cammilleri S, Durand JM, Mundler O. Guedj E, et al. Among authors: mundler o. Otol Neurotol. 2010 Jun;31(4):699-700. doi: 10.1097/MAO.0b013e31819d333b. Otol Neurotol. 2010. PMID: 19451758 No abstract available.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Among authors: mundler o. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
130 results